Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy

Annals of the New York Academy of Sciences
Tatsuo KimuraP H Gumerlock

Abstract

The hypothesis tested was that mutant tumor DNA shed into plasma would show predictive value for monitoring response to therapy in non-small cell lung carcinoma patients. Pretreatment plasma specimens from 25 patients on a phase I trial were evaluated, 12 with paired posttreatment specimens, and 138 patients on the Southwest Oncology Group S0003 trial, 38 with paired posttreatment specimens, for the presence of K-RAS mutations. Thirteen tumor specimens from the phase I trial patients and seven tumor specimens from S0003 patients were also available for comparative analysis of K-RAS mutations in tumor tissue and plasma. All patients were treated similarly with paclitaxel, and carboplatin chemotherapy. DNA was extracted and mutational analyses performed using an RFLP-PCR assay. K-RAS mutations were found in plasma DNA in 5/25 of the phase I patients (20%). Median survival was 10 months in all patients, 11.4 months in the wild-type K-RAS group, and 3.3 months in the mutant K-RAS group (P = 0.056). Point mutations in plasma DNA were identical to mutations found in the tumors, confirming the tumor as the source. In two patients with K-RAS mutations pretreatment, posttreatment plasmas were evaluated: a patient with clinical progressi...Continue Reading

References

Aug 30, 1990·The New England Journal of Medicine·R J SlebosW J Mooi
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S L GrazianoB J Poiesz
Dec 2, 1999·Journal of the National Cancer Institute·H H NelsonK T Kelsey
Mar 29, 2000·CA: a Cancer Journal for Clinicians·R T GreenleeP A Wingo
Apr 25, 2003·Methods in Molecular Medicine·Tomoya KawaguchiPaul H Gumerlock

❮ Previous
Next ❯

Citations

May 19, 2010·Biomarkers in Medicine·Barbara L Parsons, Fanxue Meng
Sep 26, 2013·International Journal of Molecular Sciences·Yahya I ElshimaliJaydutt V Vadgama
Oct 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B T LiC G Azzoli
Aug 7, 2010·Clinica Chimica Acta; International Journal of Clinical Chemistry·Klaus JungAnja Rabien
Nov 17, 2006·Annals of the New York Academy of Sciences·Xiaoyan XuePenella J Woll
Mar 1, 2005·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Mahmoud ToulanyH Peter Rodemann
Apr 25, 2007·Pathology·Jason C H Tsang, Y M Dennis Lo
Dec 2, 2006·Biochimica Et Biophysica Acta·M Fleischhacker, B Schmidt
Sep 6, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Carlos CampsRafael Rosell
Apr 2, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yung-Bin KuoErr-Cheng Chan
Nov 16, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Carlos CampsRafael Sirera
Aug 9, 2018·Archives of Pathology & Laboratory Medicine·Jing LiVictoria H Brophy
Sep 26, 2007·Expert Review of Molecular Diagnostics·Simone Helmig, Joachim Schneider
Jan 28, 2021·The Journal of Pathology. Clinical Research·Sissel Gyrid Freim WahlBjørn Henning Grønberg
Sep 26, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J García-FoncillasA Vivancos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.